About Adamas

Adamas develops new medicines to improve the daily lives of those affected by chronic neurologic disorders. Approximately 36 million people in the United States suffer from conditions such as Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s disease. Symptoms associated with these disorders can be treated sub-optimally due to tolerability issues, which may limit the amount of drug that is present when patients need relief.

Adamas has pioneered a platform to develop medicines for chronic neurologic disorders based upon an understanding of time-dependent biologic processes responsible for disease activity and drug response. We translate this understanding into medicines to provide demonstrable symptomatic relief from chronic neurologic disorders without additional tolerability issues. With this platform we:

  • discover insights about temporal patterns of disease activity and drug response
  • identify known drugs with potential activity in targeted disorders
  • invent a synchronized drug profile to match underlying disease activity and drug response patterns
  • develop new medicines that release the drug to match the desired drug profile, first as single agents and then in fixed-dose combinations
  • commercialize new products alone and with partners

Our lead program, ADS-5102,  is a high-dose amantadine, taken once-daily at bedtime, in development for levodopa-induced dyskinesia (LID) in people with Parkinson’s diseased.  A New Drug Application (NDA) supporting ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date of August 24, 2017.  ADS-5102 has additional opportunities to provide potentially symptomatic treatment of other chronic neurologic disorders such as multiple sclerosis walking impairment, post-stroke walking impairment, and several other indications. We are also investigating ADS-4101 (lacosamide) for the treatment of partial onset seizures in patients with epilepsy. Additionally, through our license to Allergan, our portfolio includes two medicines commercially available in the United States for indications relating to Alzheimer’s disease: Namzaric® (memantine hydrochloride extended-release and donepezil hydrochloride) capsules and Namenda XR® (memantine hydrochloride) extended-release capsules. Adamas is eligible to receive royalties on sales of Namenda XR and Namzaric beginning in June of 2018 and May of 2020, respectively. Our business strategy is to continue to discover, develop and commercialize new treatment solutions for patients independently or in collaboration with partners.

NAMENDA XR® and NAMZARIC® are registered trademarks of Merz Pharma GmbH & Co. KGaA.

Developing medicines to improve the daily lives of people affected by chronic neurologic disorders.

About Adamas
  • Headquarters:
    Emeryville, Calif.
  • Employees: ~80
  • Initial Public Offering: April 2014
  • Nasdaq: ADMS